Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 10, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Predicting outcomes for children with neuroblastoma.

Joëlle Vermeulen1, Katleen De Preter, Pieter Mestdagh

  • 1Center for Medical Genetics, Ghent University Hospital, Ghent, B-9000, Belgium.

Discovery Medicine
|July 31, 2010
PubMed
Summary

Accurate outcome prediction in neuroblastoma (a rare but fatal cancer) is challenging. New tumor-specific markers are needed to improve risk stratification and personalize treatment beyond current systems.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Widespread DNA off-targeting confounds RNA chromatin occupancy studies.

Nature biotechnology·2026
Same author

RUVBL1 and RUVBL2 are druggable MYC effector regulators in neuroblastoma cells.

iScience·2026
Same author

Targeting replication stress in neuroblastoma by exploiting the synergistic potential of second generation RRM2 and CHK1 inhibitors.

Cell death & disease·2026
Same author

Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: unadjusted and adjusted indirect comparisons.

Frontiers in oncology·2026
Same author

Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis.

JCO precision oncology·2026
Same author

Synergistic inhibition of CHK1 and MUS81 to combat replication stress resistance in high-risk neuroblastoma.

Scientific reports·2025

Area of Science:

  • Oncology
  • Cancer Research
  • Pediatric Oncology

Background:

  • Neuroblastoma is a significant clinical challenge, with nearly 50% of patients experiencing fatal outcomes despite advanced therapies.
  • Current risk stratification systems, based on clinical, histopathological, and biological factors, guide treatment but show limitations in predicting individual patient outcomes.
  • Discrepancies in clinical courses among patients with similar parameters highlight the need for more precise prognostic markers.

Purpose of the Study:

  • To address the limitations of existing neuroblastoma risk stratification systems.
  • To identify novel, tumor-specific prognostic markers for enhanced risk estimation at diagnosis.
  • To improve the selection of risk-adapted therapies for neuroblastoma patients.

Main Methods:

More Related Videos

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

Related Experiment Videos

Last Updated: Jun 10, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

  • Review of current clinical, histopathological, and biological factors used in neuroblastoma risk stratification.
  • Analysis of existing literature on novel prognostic markers in neuroblastoma.
  • Exploration of emerging markers such as copy number aberrations, gene expression signatures, and epigenetic markers.

Main Results:

  • Current risk stratification systems are useful but do not fully account for individual patient variability in clinical outcomes.
  • Existing systems face challenges in accurately predicting outcomes for all neuroblastoma patients.
  • The need for additional, sensitive prognostic markers is evident to refine risk assessment.

Conclusions:

  • Improved risk stratification for neuroblastoma requires the identification of new prognostic markers.
  • Novel markers, including genetic and epigenetic factors, show promise for enhancing diagnostic accuracy and therapeutic decisions.
  • Further research into these markers is crucial for optimizing neuroblastoma treatment strategies.